Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00413751

First Posted: December 20, 2006

Last Update Posted: December 20, 2006

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by:

Walter Reed Army Medical Center

Tracking Information

First Submitted Date

December 19, 2006

First Posted Date

December 20, 2006

Last Update Posted Date

December 20, 2006

Start Date

Not Provided

Primary Completion Date

Not Provided

Current Primary Outcome Measures

Not Provided

Original Primary Outcome Measures

Not Provided

Change History

No Changes Posted

Current Secondary Outcome Measures

Not Provided

Original Secondary Outcome Measures

Not Provided

Current Other Outcome Measures

Not Provided

Original Other Outcome Measures

Not Provided

Descriptive Information

Brief Title

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Official Title

Not Provided

Brief Summary

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Detailed Description

Not Provided

Study Type

Observational

Study Design

Time Perspective: Longitudinal
Time Perspective: Prospective

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Not Provided

Study Population

Not Provided

Condition

Healthy

Intervention

Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Study Groups/Cohorts

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status

Completed

Enrollment

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria

Inclusion Criteria:

Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

Patients not meeting above stated age criteria
Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
History of serious ocular, neurological, cardiovascular disease
History of severe systemic disease
History of arrhythmias or high blood pressure
Patients currently taking any type of ocular or systemic medications except multivitamins.
Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Sex/Gender

Sexes Eligible for Study:

All

Ages

18 Years to 50 Years (Adult)

Accepts Healthy Volunteers

Yes

Contacts

Contact information is only displayed when the study is recruiting subjects

Listed Location Countries

United States

Removed Location Countries

Administrative Information

NCT Number

NCT00413751

Other Study ID Numbers

WRAMC WU #03-23004

Has Data Monitoring Committee

Not Provided

U.S. FDA-regulated Product

Not Provided

IPD Sharing Statement

Not Provided

Responsible Party

Not Provided

Study Sponsor

Walter Reed Army Medical Center

Collaborators

Not Provided

Investigators

Principal Investigator:

KRAIG S. BOWER, MD

Walter Reed Army Medical Center

PRS Account

Walter Reed Army Medical Center

Verification Date

December 2006

To Top